Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for ...

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Germany-based Bayer’s wholly-owned gene therapy company AskBio today announced that its investigational gene therapy AB-1005 ...

Danish pharma major Novo Nordisk has sued KBP Biosciences and its founder and executive chairman, Huang Zhenhua, for $830 ...

Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) ...

US biotech Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK ...

Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to Dutch clinical-stage drug ...

US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending ...

According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...